Cognition Therapeutics Co-Founder and CSO Susan Catalano to Present at Sachs Neuroscience Innovation Forum


Elusive or Not, Aβ Oligomers Are in BioPharma Crosshairs

ALZ Forum

Potential Therapy, CT1812, Seen as Safe and Able to Target Disease Markers, Cognition Reports

Alzheimer’s News Today

Cognition Therapeutics CEO Kenneth I. Moch to Present at the Stifel 2017 Healthcare Conference


Cognition Therapeutics CEO Kenneth I. Moch to Present at the Stifel 2017 Healthcare Conference


Cognition Therapeutics’ Alzheimer’s Disease Candidate CT1812 Meets Phase 1b/2a Study Objectives: Well Tolerated with Positive Influence on Biomarkers of Synapse Recovery


Cognition Therapeutics to Present Results of CT1812 Phase 1b/2a Clinical Study as Late Breakers at CTAD Meeting on November 2nd and 4th

Globe Newswire

Cognition Therapeutics Announces Issuance of Broad Composition of Matter Patent for CT1812, a First-in-Class Alzheimer’s Disease Clinical Candidate

Globe Newswire

FDA Places CT1812, Potential Disease-Modifying Alzheimer’s Treatment, on Fast Track

Alzheimer’s Today

First-in-Class Alzheimer’s Drug Gets Fast-Tracked by FDA


Cognition Therapeutics Receives Fast Track Designation From U.S. FDA For First-In-Class Alzheimer’s Candidate, CT1812

Clinical Leader

Cognition Therapeutics Receives Fast Track Designation from U.S. FDA for First-in-Class Alzheimer’s Candidate, CT1812


Cognition Therapeutics CEO Kenneth I. Moch Hosting One-on-Ones at Mizuho Securities CNS Deep Management Day

Globe Newswire

Function of Cognition Therapeutics’ Neurological Drug Screening Platform Presented at American Chemical Society National Meeting

Globe Newswire

Cognition Therapeutics Elects Lazard Vice Chairman Stephen Sands to Board of Directors

Globe Newswire

Lazard exec joins Cognition Therapeutics board

Pittsburgh Business Times

Cognition Therapeutics CEO Kenneth I. Moch to Present at Canaccord Genuity Annual Growth Conference

Globe Newswire

Cognition Therapeutics Reports Drug-Drug Interaction Results for CT1812, a Disease-Modifying Alzheimer’s Disease Candidate

Globe Newswire

Cognition Therapeutics $6.50 million Financing


Cognition Therapeutics aims to stop memory loss with breakthrough Alzheimer’s drug

click here

Cognition Therapeutics initiates U.S. testing for Alzheimer’s Drug

click here

Cognition Therapeutics Initiates US Clinical Testing Of CT1812, A Novel Small Molecule For The Potential Treatment Of Alzheimer’s Disease

click here

Cognition Therapeutics initiates US clinical testing of CT1812, a novel small molecule for the potential treatment of Alzheimer’s disease

click here

Cognition Therapeutics to Highlight CT1812 Safety Data at the 9th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting

click here

CogRX: Society for Neuroscience 2016 Annual Meeting Nanosymposium Explores Potential of “Sigma-2/PGRMC1 Receptor Function in Disease and Therapeutics”

click here

Form D To Observe: Cognition Therapeutics $3.00 million Financing. Kenneth I Moch Submitted Nov 30 Filing

click here

CogRX: 1st Alzheimer’s Patient Dosed in Clinical Trial of Amyloid Beta ‘Displacer’

click here

CogRx sees Lilly solanezumab results support for its unique mechanism for Alzheimer’s disease treatment

click here

Cognition Therapeutics Sees Lilly Solanezumab Clinical Trial Results as Support for its Unique Mechanism for Treatment of Alzheimer’s Disease

click here

Cognition Therapeutics Announces Dosing of First Alzheimer’s Patient in Phase 1b Trial of CT1812

click here

Alzheimer’s Drug Development Company Cognition Therapeutics appoints Kenneth I. Moch President & CEO

click here

Cognition Therapeutics: Cognitive impairment pipeline market analysis H2 2016 examined in new market research report

click here

Cognition Therapeutics launching clinical trials for Alzheimer’s drug in Australia

click here

Cognition Therapeutics: Five things to know today

click here

Cognition Therapeutics (CogRx) Receives Michael J. Fox Foundation Grant to Study Inhibitors of Alpha-synuclein Oligomers for the Treatment of Parkinson’s Disease

click here

Drug development is on the rise in Pittsburgh, but there’s room to grow

click here

Cognition Therapeutics Receives Prestigious Luis Villalobos Award from Angel Capital Association

Named after Tech Coast Angels’ inspiring co-founder, the annual award goes to most outstanding and innovative early stage  company

May 18, 2016 – IRVINE, Calif. – Tech Coast Angels (TCA) today announced that the Angel Capital Association (ACA) had awarded the Luis Villalobos Award to Cognition Therapeutics at the annual ACA Summit last week in Philadelphia.

The award recognizes the single-most ingenious and innovative company that is financed by one of ACA’s member angel groups. It is the highest honor available for an early-stage company to receive from the Angel Capital Association, and honors Tech Coast Angels co-founder, Luis Villalobos.  Mr. Villalobos was a leading light in the angel investment field, by educating and mentoring numerous entrepreneurs and making nearly 60 personal investments, prior to his death in 2009.

Members in all five of TCA’s networks, as well as TCA’s ACE Fund 1, have invested in Cognition Therapeutics.  The company, based in Pittsburgh, focuses on the discovery and development of small molecule therapeutics targeting the toxic proteins that cause the cognitive decline associated with Alzheimer’s disease and other human neuro-degenerative diseases.

“Of all of our TCA Portfolio companies, Cognition Therapeutics is one of the most responsible and transparent companies that our members have invested in,” said John Murphy, TCA’s deal lead for Cognition Therapeutics. “Their science has continuously advanced at a rapid and successful pace. They regularly update us on their progress, apprising us of Cognition’s status as well as the industry’s. Several times a year, every year, they host conference calls so that we stay current on how they are doing. They then follow up with face-to-face meetings with all our chapters. They are a prime example of what an Angel Syndicate investment should be, and to date all of their funding has been through Angel groups.”

Other winners of the Luis Villalobos Award include RetroSense Therapeutics (2015), EyeVerify (2014), TRX Systems (2013), AssureRx (2012), Quantum Dental Technoloiges (2011) and Modumental (2010-inaugural year for the award).

Cognition Therapeutics Receives Prestigious Luis Villalobos Award from Angel Capital Association

Click here

Angels hail Pittsburgh company Cognition Therapeutics as most innovative startup

click here

Pittsburgh Life Sciences Greenhouse Portfolio Company Cognition Therapeutics Wins Angel Capital Association’s Luis Villabos Award

click here

Tech Coast Angels Invested Best Ever $16.37 Million in 2014

Southern California Angel Network Surpasses Previous Records for Both Investments and Activity

IRVINE, Calif. January 29, 2015 Tech Coast Angels (TCA) invested a total of $16,373,337 in 61 total deals in Calendar Year 2014. The angel network announced that 2014 was the most active year since the networks inception in 1997 for number of deals funded, and capital raised was also the largest ever. TCAs five networks throughout Southern California invested in a variety of industries last year, including consumer goods, healthcare, biotechnology, HIPAA-compliant data storage, social networking, organic agriculture, and automobile technology.In 1H 2014, TCA investments totaled $6,321,874 in 27 total deals. 2H 2014 saw a nearly 60% increase in the amount of total investment from the first half of the year, with $10,051,463 in 34 total deals. Compared to 2013, the angel network increased its total investment portfolio by nearly 12%, from $14,639,612 million in 2013 to $16,373,337 in 2014.After four successful exits in 2013 (Cognition Technologies, Green Dot, Lend Amend and Trius Therapeutics), 2014 brought five more positive exits with AIRSIS, Allylix, Bluebeam Software, Hookit (formerly Loopd Networks), and Mindbody Software. TCAs portfolio of new deals for 2014 include: Aggregage, Apeel Sciences, Ascendant Spirits, Beacon Healthcare, Edufii, Fusion Brake, GoBookIt, ImmunoGum, iPourIt, LeaseLock, Neural Analytics, Parcel Pending, Perfectna, Portfolium, Respiratory Motion, RetroSense Therapeutics, Ring Router, Schlep & Fetch, Soma Bar, Spine Innovation, The Influential Network, TrueVault, Unlicensed Chimp Technology, and WeGoLook. “We are excited by the quality and unique breadth and scope of these great, young, mostly Southern Californian companies that we can support through our experience and capital, said Michael Green, TCA incoming chairman. “We look forward to continuing to find, hone and cultivate the many outstanding early-stage companies in our community in 2015.

Tech Coast Angels Invests More Than $4.5 Million in 1H 2012

Largest Angel Network in United States Invests in 17 Innovative Companies Across Broad Range of Industries

IRVINE, Calif. – August 15, 2012 – Tech Coast Angels (TCA) raised more than $10 million of total investment in 17 innovative companies, including $4,571,000 of direct TCA investment, during the first half of 2012 via the group’s five networks (Los Angeles, Orange County, San Diego, Central Coast, and Inland Empire). The investment portfolio for the period spans a wide spectrum of young, innovative companies — from mobile advertising platforms and social loyalty marketing, to biopharmaceuticals and organic plant food.

Companies funded by TCA in the first six months of 2012 are: Active Life Scientific, Cadence Biomedical, Cashie Commerce, Cognition Therapeutics, Emerald Logic, ExtendCredit, Gemmus Pharma, GridTest Systems, H2scan, Hipmunk, Pagewoo, PetPlay, Social Annex, Social Rewards, ViroPan, Vokle, and Wasatch Microfluidics.   

Compared to the same period in 2011, the group maintained a consistent level of support and funding to the same number of young, fast-growth companies (in 1H 2011, TCA invested in 17 companies for $4.4 million, with a total investment of $11.9 million).

“TCA is a valuable, receptive resource for promising companies.  By providing early funding, mentorship and strategic support to early-stage entrepreneurs, particularly in a risk- and investment-averse business environment, we help foster innovation and entrepreneurship throughout our communities,” said Stephen Flaim, Ph.D., FACC, FAHA, chairman of Tech Coast Angels. 

TCA also expressed its support for the recent rise of accelerators and incubators in Southern California.  “We don’t view accelerators as competition; it’s quite the opposite. We embrace their place in the startup ecosystem,” continued Flaim. “Companies graduating from accelerators have fine-tuned product market fit, customer acquisition, go-to-market strategy and their business model.  TCA is often a critical next-step funding source for these companies.” 

“TCA looks forward to sharing capital and experience with more young entrepreneurs in the second half of 2012,” said Flaim. “Our members continue to explore opportunities to invest in and support diverse and exciting companies.” 


IRVINE, Calif., February 22, 2011 Tech Coast Angels (TCA), the nations largest angel investment network, today announced it funded 31 investments, including 12 new deals and 19 follow-on investments in a broad range of start-up businesses, demonstrating its angel investment leadership. TCA raised over $40 million of total investment for its entrepreneurial companies, including over $6 million through direct TCA investment and approximately $33.9 million through other sources of venture and angel capital. The total number of investments is up significantly from 2009 when 24 deals were completed. In addition, 2010 marked a year of profitable exits for TCA portfolio companies, including an IPO for Green Dot Corporation (NYSE: GDOT) that yielded over 100x return for early investors, the acquisition of Language Weaver Inc. by SDL for $42.5M, and an IPO for Trius Therapeutics (NASDAQ: TSRX).

“This past year was a dynamic time in our history. Coming out of an economic recession, we turned the tide and invested in more innovative, game-changing entrepreneurial companies and experienced several profitable exits. This is the result of our commitment to making the angel funding process faster, easier and more accessible to entrepreneurs to generate more investment. Weve streamlined the process and added new events and opportunities for entrepreneurs to connect with our members, said Mike Napoli, Chairman, Tech Coast Angels. “The entrepreneurial community in Southern California is growing dramatically and Tech Coast Angels is committed to identifying the brightest, most innovative new companies and fostering their growth through both capital investment and mentoring leadership. Already, 2011 is shaping up to continue on this upward trend.

This years investment portfolio represented companies in a wide number of growth industries including technology, biotech and pharmaceutical, social media, financial services, consumer products, and green technologies, among others. The companies funded by Tech Coast Angels in 2010 included: Cyber-Rain; Benchmark Revenue; Allylix; Outside Labs; Vigilistics; H2Scan; Mobile XL; Continental Windpower; Amplyx; OlFactor; Vokle; Micropower Technologies; HitFix; Ranker; CardioCreate; MyShape; Bikestation; MasherMedia; Brand America; Intrastage; YouMail; Glassbeam; LaughStub; Ondax; Cosnet; Solulink; and Cognition Therapeutics.

TCA portfolio company Cognition Therapeutics Completes $2.5M in Series A1 Financing to Advance Alzheimer’s Disease Drug Treatment Program

PITTSBURGH, Jan. 20, 2011 /PRNewswire/ — Cognition Therapeutics Inc., a drug discovery company developing novel, small molecule disease-modifying treatments for Alzheimer’s, has closed on a $2.5 million Series A1 financing it will use to bring one or more of its compounds to Investigational New Drug (IND) candidate status. The round was led by Golden Seeds, one of the nation’s largest angel investing groups, and was syndicated with Tech Coast Angels.

New investors in the A1 financing include The Breedlove Limited Family Partnership and TMC Investment Company, an investment division of the Tippins family, both located in Pittsburgh. All existing investors participated in the round including Ogden CAP Associates, M5Invest, the Pittsburgh Life Sciences Greenhouse and Innovation Works. The round was comprised of new investment and conversion of convertible debt.

This financing increases our investor base and further expands our national network to support the critical work we are doing to identify drugs that can treat and potentially prevent the progression of Alzheimer’s disease,” said Cognition Therapeutics President and CEO Hank Safferstein, Ph.D., J.D. “We’re pleased to welcome Golden Seeds, Tech Coast Angels and several western Pennsylvania community leaders in supporting our pioneering approach to drug discovery for Alzheimer’s disease and related conditions of the central nervous system. We are also fortunate to have Dr. Nada Jain, Managing Director of Golden Seeds and Mr. Mark Breedlove, President and CEO of Keystone Profiles, joining our existing Board of Directors, providing additional business insight and guidance to the company.”

“The drug candidates Cognition Therapeutics is developing represent new approaches that have the potential to make a major impact on the treatment of Alzheimer’s disease, and other central nervous system disorders,” said Dr. Jain. “The company has received positive peer review and has obtained significant grant funding in its early development, and we are delighted to be the syndication lead in this financing round. Alzheimer’s affects 4.5 million people in the United States today, with that number expected to exceed 12 million by 2050.”

Funds raised in this round will support preclinical work required for IND candidate selection, and enable Cognition Therapeutics to further exploit novel molecular targets and pathways identified through the company’s phenotypic screens.

“Our drug leads selectively block the activity of the toxic oligomeric form of Abeta protein that interferes with normal learning and memory,” said Susan Catalano, Ph.D., Cognition Therapeutics Chief Science Officer. “Studies from the world’s leading academic laboratories indicate that the memory deficits caused by this oligomeric protein are among the earliest changes seen in Alzheimer’s and Mild Cognitive Impairment, the precursor to Alzheimer’s. These studies indicate that blocking the effects of this protein may halt or reverse Alzheimer’s disease.”

Cognition has developed a number of screening strategies to identify small molecules capable of blocking the central toxicity of proteins in Alzheimer’s disease and other neurodegenerative diseases. These assays emphasize phenotypic or functional responses of mature primary neurons to the toxic proteins. Cognition’s proprietary chemistry platform converts natural product molecular scaffolds into low molecular weight chemically stable drug-like molecules, and is thus a source of novel pharmacophores and valuable drug candidates.

“The registration of the company’s proprietary biological screening approach with positive results in an animal model of Alzheimer’s disease is a significant achievement,” said Dr. Cynthia Lemere, Associate Professor of Neurology at Harvard University’s Brigham & Women’s Hospital and member of Cognition’s Scientific Advisory Board. “Cognition’s scientific approach is unique in the industry and has generated exciting results that the Alzheimer’s research community is watching closely. Further development of these potentially disease-modifying drugs is very welcome,” Dr. Lemere continued.


Tech Coast Angels Companies Receive More Than $1B

30 TCA Portfolio Companies Secure More Than 75M in 2008

LOS ANGELES – February 23, 2009 – Tech Coast Angels (TCA), the largest angel network in the United States, today announced that more than $1B has been invested in TCA-funded companies since the group’s inception in 1997. TCA members have personally invested more than $99M and venture capital firms and other private equity investors have contributed more than $960M. The number of companies financed by Tech Coast Angels members was up last year over 2007. In 2008, companies received more than $75M in 15 first-time financings and 16 follow-on rounds from TCA members and affiliated investors, compared with 12 first-time and 14 follow-on rounds completed in 2007.
“TCA is still actively investing, despite the downturn in the economy. Our membership continues to be the largest single source of first-time deal financings for early stage companies in Southern California,” said Ralph Mayer, newly elected chairman of TCA. “2008 was a banner year for TCA. We reached the $1 billion mark and increased the number of companies funded year-over-year, which further demonstrates our commitment to the Southern California ecosystem.”

Companies receiving 2008 first-time investments or follow-on rounds from TCA and its network of venture capital partners include Agilenano, AIRSIS, Amplyx Pharmaceuticals, Axiotron, Bikestation, BrandAmerica, BrightQube, CardioCreate, CaseStack, Clupedia, Cognition, Cyber-Rain, Dayak, Edgeware Analytics, eGuardian, EZ-Assure, H2Scan, Make It Work, MicroPower Appliance, Mobile-XL, MojoPages, MyShape, Opposing Views, Santrio, SodaHead, TherMark, Trius Therapeutics, WiSpry, Wise Window and Zubican

“History has shown that downturns in the economy are often the best time to start a new company, which is one of the reasons TCA members are still actively investing,” said Al Schneider, president of TCA’s Los Angeles network. “Since our members provide entrepreneurs with many more benefits than just capital, funding from TCA’s members is even more valuable to companies in these challenging economic times.”
The Tech Coast Angels Los Angeles network is hosting its fourth annual Fast Pitch Competition and networking event on February 24 from 5-9 p.m. at UCLA Anderson School of Management. Fast Pitch is a competition among 12 carefully selected entrepreneurs who will each deliver a 90-second company pitch to a panel of investors and other members of Southern California’s entrepreneurial community. For more information, visit

About Tech Coast Angels

Tech Coast Angels,, the largest angel investor network in the United States, provides funding and guidance to more early-stage, high-growth companies in Southern California than any other investment group. Since its inception in 1997, TCA members have focused on building valuable companies, personally invested more than $99M, and helped portfolio companies attract more than $960M in additional capital, mostly from venture capital firms. TCA members give companies more than just capital; they also provide counsel, mentoring and access to an extensive network of potential investors, customers, strategic partners and management talent. TCA has more than 300 members, including its venture capital affiliates, in five networks in Los Angeles, Orange County, San Diego, Westlake/Santa Barbara and the Inland Empire.